ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) COO Brendan Teehan sold 548 shares of the stock in a transaction on Monday, May 1st. The shares were sold at an average price of $21.18, for a total transaction of $11,606.64. Following the transaction, the chief operating officer now owns 9,487 shares of the company’s stock, valued […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) – Equities researchers at Cantor Fitzgerald increased their FY2023 earnings per share (EPS) estimates for shares of ACADIA Pharmaceuticals in a note issued to investors on Thursday, April 27th. Cantor Fitzgerald analyst C. Duncan now forecasts that the biopharmaceutical company will post earnings of ($0.40) per share for […]
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) had its target price increased by Credit Suisse Group from $93.00 to $95.00 in a report published on Friday morning, The Fly reports. Several other equities analysts have also recently issued reports on the company. Mizuho reaffirmed a neutral rating and set a $20.00 price objective on shares of […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating)’s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $21.90 and last traded at $21.39, with a volume of 178527 shares changing hands. The stock had previously closed at $21.75. Analysts Set New Price Targets Several research analysts […]
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) was the target of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 9,610,000 shares, a growth of 17.5% from the March 31st total of 8,180,000 shares. Based on an average trading volume of 1,590,000 shares, the […]